Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Gixer,
As regards your second paragraph below, am I right in thinking that, under the new arrangements Provexis will be responsible for the supply of the straight ingredient of FF to DSM for use in DSM's Premix solutions (once their existing supplies of stock are exhausted).
In other words will DSM become a direct customer of Provexis?
As far as I know there is no guidance available and there has only been one sub-trial from by-health that comments on the clotting time of blood for FF Users. However, I did undergo some elective surgery last year when the surgeon found out that I was using FF and postponed the surgery for a minimum period of 2 weeks because they were concerned that FF could affect clotting times.
Very strange isn't it. It is definitely listed as an ingredient. However, the product is sold as a scalp tonic (to be massaged in).
Have this norwegian company done some research that identifies that fruitflow can be administrered externally and that it is efficaceous in preventing hairloss???
Let's hope that Provexis can rush to resupply these products by using up some of the new stock that it has just purchased from DSM. The quicker that they can sell this stock, the less impact there will be on cashflow, and that will mean a reduced requirement for new funding or debt AND, hopefully, a quicker march into profitability.
Am I being too hopeful here?
I had Covid during the spring of 2022 and am a regular taker of Fruitflow. However, what is quite interesting is that I was forced to stop taking FF prior to surgery and I actually contracted it during this period.
Thanks Gixer,
I am assuming (hoping!!!!) that some of the studies, that you have recently highlighted in here, represent the results of the "missing" studies from the long awaited "Blue Cap" submission.
Whatever happens next, I for one am becoming more and more positive about the future.
Thanks for your ongoing research and a very Happy New Year.
Slam
With all of these new developments has anyone tried to work out what the value of our IP and Patents is?
I am fairly certain that if someone wanted to buy the IP, it would cost significantly more than £19M (the current market cap of the Company). To an extent, that merely shows how ineffective the marketing of this product has been and just backs up some of the comments below.
I read this as being mainly or even wholly optimistic too:
The revised agreement with DSM is a slightly pleasant surprise and put the control of the development of the existing market place firmly in our hands at a time when FF is starting to gain some ground in product awareness;
The development of FF in the "Gut Microbiome" market definitely caught me by surprise and the additional patent will add value to the underlying IP. It is interesting that DSM still wish to maintain control over this aspect of the product - but that can only be a good thing in terms of developing the market AND increasing the brand awareness.
The references to the progress in the development of the BH agreement shows no signs of a downside - indeed the update on the progress of the SAMR approval is positive and would appear to fit wholly within the timescale for the launch of the Agreement in Jan 2023;
A significant decrease in the financial loss for the last year. The possibility of reaching profitability of 23 or 24, and the chance that we will be spared a future fund raiser.
a huge derisk imho.
Thanks Gixer, I thought I had made both of those points, but you have put it much better than I did.
There was one other point that I forgot to include:
In my mind there are two issues that could be transformational to the SP. I mentioned the first - being the gradual move to long term profitability of the Company in it's existing markets.
The second, would be a potential rerating of the value of our underlying Patents. To my mind, the confidence shown by BH in the product itself indicates that the underlying value of the Parent Patents is significantly greater than the current SP. I hope that investors will come to make a similar observation.
Like Gixer, I am not sure what the rationale with the apparent bombardment of new articles but it is interesting that they appear on a number of different platforms ( from dietary supplement platforms, clinical research platforms to Investment Platforms).
I agree with Gixer, that they all appear to emanate from BH even though they are not all credited to them. My main thought is that BH are simply using it as a "brand awareness" campaign probably prior to a launch in 2023. Obviously they still need to achieve blue cap status before they can full launch any new products into the Chinese market - maybe they are also trying to convince the authorities about the efficacy of the Fruitflow product AND to push the "platelet aggregation" issue in an attempt to obtain official approval for a new food supplement function under SAMR.
But who knows?????
The one thing that I have taken the most heart from is that it seems apparent that BH seem confident in the product - both as an efficacious dietary supplement (even with the potential to incorporate it into mainline medicine) and presumably as a profitable future income stream!!!! It is such a shame that neither Provexis nor DSM could have given us this amount of brand awareness in the existing marketplace.
As a LTH, I always been looking for an event that would be transformational for the SP. We have ground on for years with very little information forthcoming but the last 18 months have made me a little more confidedent that something might happen and we now have a few more developments that could provide the key that we have needed:
1) We are very slowly approaching profitability in the current market
2) We are awaiting a new arrangement with DSM - but we know that this could involve taking over the production of the product itself.
3) We are awaiting the grant of Blue Hat status in the Chinese Market
4) As a result of (3) we are also awaiting the launch of new products into the Chinese Market - possibly the biggest market for Holistic medicine in the world
5) We are awaiting details of the final agreement with BH.
But, again as Gixer says, WHO KNOWS!!!!
By Health are funding an awful lot of studies on the differing effects of WSTE, and Some of these studies would appear to be pushing the use of WTSE into mainstream medicine too.
I sometimes wonder who will own the IP rights for some of these results. I am not sure that it matters too much as Provexis do own the parent IP.
Whatever way it turns out, BH are certainly pushing the awareness of WTSE (at least to the Chinese population and that can only be good for us in the long (or even medium) term.
Those two share trades could be associated with the issue of 7M shares as notified in the latest RNS. It could even be a false sell and a false buy, if the shares were transferred to the consultant referred to in the RNS.
Hi All,
Just a word of warning. I was due to have an elective surgery on Friday (Hip Op). The operation was cancelled at the last minute because they were concerned that my blood didn't clot quickly enough and this was put down to the fact that I had been taking FF up to the day before the Operation. I had previously advised the hospital I was taking FF but no one had heard of it and didn;t warn me to cease taking it beforehand.
https://www.theguardian.com/commentisfree/2022/jan/05/long-covid-research-microclots
This is the first time I have seen research of this nature. I wonder whether FF is effective against them
Another article suggesting that the therapeutic (anti-coagulation) properties of fruitflow have a positive impact in restricting the major effects of Covid-19.
Although not yet clinically proven, each successive article is pointing more and more directly to the correlation. IMO It is understandable why BH are looking to include the new health claim in the Blue cap application and you can see the beginnings of a significant push for the product.
It is really good to be given a much more detailed insight into the current Patents that are in operation, together with a synopsis of the activity in securing new Patents over the last 12 Months. Two if the "Patent Family" are even granted in China (which was always a concern of mine).
It is my belief that the value of the Company lies entirely in the nature of the Patents that are held.
Indeed, if you strip out the R&D costs from the Accounts (which presumably represents, in the main, the cost of securing the new patents) you could even go so far as to say that Provexis is now Operating In Profit.
It is good to see some sort of timescale attributed to the SAMR approval process even if that timescale is longer than we hoped.
Downside risk of slight concern is the renegotiation of the DSM Agreement - that could go either way.
Just for the sake of conjecture, I wonder what the legal position would be if BY-Health decided to do the studies and trials in China. I am presuming here that Provexis already own the IP/patents on the various "supplements" properties of FF. However, if BY-Health crossed the IP over into "mainstream medicines", would the IP transfer to them.